Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

5(62.5%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

8Total

N/A(5)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06796504Not ApplicableRecruiting

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Role: lead

NCT04539964Phase 3Active Not Recruiting

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Role: lead

NCT07489326Not Yet Recruiting

The SetPoint System Safety & Performance Post-Approval Study

Role: lead

NCT04862117Not ApplicableActive Not Recruiting

Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

Role: lead

NCT03437473Not ApplicableCompleted

Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

Role: lead

NCT02951650Phase 1Unknown

Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease

Role: lead

NCT02311660Not ApplicableUnknown

Vagus Nerve Stimulation in Crohn's Disease

Role: lead

NCT01552941Not ApplicableCompleted

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Role: lead

NCT01552538Phase 1Unknown

Long Term Extension Study For SPM-005 Participants

Role: lead

All 9 trials loaded